Brief review: Chemotherapy-induced painful peripheral neuropathy (CIPPN): Current status and future directions

Canadian Journal of Anesthesia

Volumn 61, Issue 8, 2014, Pages 754-762

  Massey, Robert L ^a   Kim, Hee Kee ^a   Abdi, Salahadin ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; AMIFOSTINE; AMITRIPTYLINE; BORTEZOMIB; CAPSAICIN; CISPLATIN; CITALOPRAM; CORTICOTROPIN; DIETHYLDITHIOCARBAMIC ACID; DIMESNA; DULOXETINE; ERYTHROPOIETIN; GABAPENTIN; GLUTAMINE; GLUTATHIONE; INDOMETACIN; LEVACECARNINE; LIDOCAINE; NARCOTIC ANALGESIC AGENT; NORTRIPTYLINE; OXALIPLATIN; OXCARBAZEPINE; PACLITAXEL; PREGABALIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ACUPUNCTURE; ANALGESIA; ANALGESIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APPLICATION SITE REACTION; BEDTIME DOSAGE; BLURRED VISION; BRIEF PAIN INVENTORY; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED PAINFUL PERIPHERAL NEUROPATHY; CLINICAL FEATURE; CONSTIPATION; DIZZINESS; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DOSE INCREASE; DRUG INDUCED DISEASE; ERYTHEMA; HUMAN; HYPERTENSION; IMMUNOCOMPETENT CELL; MASSAGE; MCGILL PAIN QUESTIONNAIRE; NAUSEA; NERVE ENDING; NEUROPATHIC PAIN; NONHUMAN; OCCUPATIONAL THERAPY; ORTHOSTATIC HYPOTENSION; PAIN ASSESSMENT; PERIPHERAL NEUROPATHY; PHYSICAL EXAMINATION; PHYSIOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SEDATION; SENSORY NERVE CELL; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; SPINAL GANGLION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URINE RETENTION; XEROSTOMIA; CHEMICALLY INDUCED; NEOPLASMS; NEURALGIA; PAIN;

ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; NEURALGIA; PAIN;

EID: 84904536866     PISSN: 0832610X     EISSN: 14968975     Source Type: Journal    
DOI: 10.1007/s12630-014-0171-4     Document Type: Review

References (86)

1. Bokhari F, Sawatzky JA. Chronic neuropathic pain in women after breast cancer treatment. Pain Manag Nurs 2009; 10: 197-205.
2. Polomano RC, Farrar JT . Pain and neuropathy in cancer survivors. Cancer Nurs 2006; 29(2 Suppl): 39-47.
3. Reyes-Gibby C, Morrow PK, Bennett MI, Jensen MP, Shete S. Neuropathic pain in breast cancer survivors: using the ID pain as a screening tool. J Pain Symptom Manage 2010; 39: 882-9.
4. Smith EM, Pang H, Cirrincione C, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 2013; 309: 1359-67.
5. Golan-Vered Y, Pud D. Chemotherapy-induced neuropathic pain and its relation to cluster symptoms in breast cancer patients treated with paclitaxel. Pain Pract 2013; 13: 46-52.
6. Boyette-Davis JA, Cata JP, Driver LC, et al. Persistent chemoneuropathy in patients receiving the plant alkaloids paclitaxel and vincristine. Cancer Chemother Pharmacol 2013; 71: 619-26.
7. Cooney MA, Culleton-Quinn E, Stokes E. Current knowledge of pain after breast cancer treatment: a systematic review. Pain Manag Nurs 2013; 14: 110-23.
8. Costigan M, Scholz J, Woolf CJ. Neuropathic pain: a maladaptive response of the nervous system to damage. Ann Rev Neurosci 2009; 32: 1-32.
9. Siau C, Xiao W, Bennett GJ. Paclitaxel- and vincristine-evoked painful peripheral neuropathies: loss of epidermal innervation and activation of Langerhans cells. Exp Neurol 2006; 201: 507-14. (Pubitemid 44344243)
10. Boyette-Davis J, Dougherty PM. Protection against oxaliplatin-induced mechanical hyperalgesia and intraepidermal nerve fiber loss by minocycline. Exp Neurol 2011; 229: 353-7.
11. Seltzer Z, Devor M. Ephaptic transmission in chronically damaged peripheral nerves. Neurology 1979; 29: 1061-4. (Pubitemid 9174475)
12. Dougherty PM, Cata JP, Burton AW, Vu K, Weng HR. Dysfunction in multiple primary afferent fiber subtypes revealed by quantitative sensory testing in patients with chronic vincristine-induced pain. J Pain Symptom Manage 2007; 33: 166-79. (Pubitemid 46186866)
13. Pal PK. Clinical and electrophysiological studies in vincristine induced neuropathy. Electromyogr Clin Neurophysiol 1999; 39: 323-30. (Pubitemid 29425922)
14. Carozzi VA, Canta A, Oggioni N, et al. Neurophysiological and neuropathological characterization of new murine models of chemotherapy-induced chronic peripheral neuropathies. Exp Neurol 2010; 226: 301-9.
15. Adelsberger H, Quasthoff S, Grosskreutz J, Lepier A, Eckel F, Lersch C. The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons. Eur J Pharmacol 2000; 406: 25-32.
16. Grolleau F, Gamelin L, Boisdron-Celle M, Lapied B, Pelhate M, Gamelin E. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol 2001; 85: 2293-7. (Pubitemid 32440704)
17. Park SB, Krishnan AV, Lin CS, Goldstein D, Friedlander M, Kiernan MC. Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. Curr Med Chem 2008; 15: 3081-94.
18. Meijer C, de Vries EG, Marmiroli P, Tredici G, Frattola L, Cavaletti G. Cisplatin-induced DNA-platination in experimental dorsal root ganglia neuronopathy. Neurotoxicology 1999; 20: 883-7. (Pubitemid 30091215)
19. Gregg RW, Molepo JM, Monpetit VJ, et al. Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol 1992; 10: 795-803.
20. Argyriou AA, Koltzenburg M, Polychronopoulos P, Papapetropoulos S, Kalofonos HP. Peripheral nerve damage associated with administration of taxanes in patients with cancer. Crit Rev Oncol Hematol 2008; 66: 218-28.
21. Peters CM, Jimenez-Andrade JM, Jonas BM, et al. Intravenous paclitaxel administration in the rat induces a peripheral sensory neuropathy characterized by macrophage infiltration and injury to sensory neurons and their supporting cells. Exp Neurol 2007; 203: 42-54. (Pubitemid 44830029)
22. Flatters SJ, Bennett GJ. Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction. Pain 2006; 122: 245-57. (Pubitemid 43729476)
23. Melli G, Taiana M, Camozzi F, et al. Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy. Exp Neurol 2008; 214: 276-84.
24. Broyl A, Corthals SL, Jongen JL, et al. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol 2010; 11: 1057-65.
25. Sun X, Windebank AJ. Calcium in suramin-induced rat sensory neuron toxicity in vitro. Brain Res 1996; 742: 149-56. (Pubitemid 27016017)
26. Siau C, Bennett GJ. Dysregulation of cellular calcium homeostasis in chemotherapy-evoked painful peripheral neuropathy. Anesth Analg 2006; 102: 1485-90.
27. Xiao W, Boroujerdi A, Bennett GJ, Luo ZD. Chemotherapyevoked painful peripheral neuropathy: analgesic effects of gabapentin and effects on expression of the alpha-2-delta type-1 calcium channel subunit. Neuroscience 2007; 144: 714-20. (Pubitemid 44856756)
28. Matsumoto G, Ichikawa M, Tasaki A, Murofushi H, Sakai H. Axonal microtubules necessary for generation of sodium current in squid giant axons: I. Pharmacological study on sodium current and restoration of sodium current by microtubule proteins and 260 K protein. J Membr Biol 1984; 77: 77-91. (Pubitemid 14223624)
29. Nieto FR, Entrena JM, Cendan CM, Pozo ED, Vela JM, Baeyens JM. Tetrodotoxin inhibits the development and expression of neuropathic pain induced by paclitaxel in mice. Pain 2008; 137: 520-31. (Pubitemid 351970170)
30. Ghelardini C, Desaphy JF, Muraglia M, et al. Effects of a new potent analog of tocainide on hNav1.7 sodium channels and in vivo neuropathic pain models. Neuroscience 2010; 169: 863-73.
31. Descoeur J, Pereira V, Pizzoccaro A, et al. Oxaliplatin-induced cold hypersensitivity is due to remodelling of ion channel expression in nociceptors. EMBO Mol Med 2011; 3: 266-78.
32. Alessandri-Haber N, Dina OA, Joseph EK, Reichling DB, Levine JD. Interaction of transient receptor potential vanilloid 4, integrin, and SRC tyrosine kinase in mechanical hyperalgesia. J Neurosci 2008; 28: 1046-57. (Pubitemid 351186354)
33. Ta LE, Bieber AJ, Carlton SM, Loprinzi CL, Low PA, Windebank AJ. Transient receptor potential vanilloid 1 is essential for cisplatin-induced heat hyperalgesia in mice. Mol Pain 2010; 6: 15.
34. Anand U, Otto WR, Anand P. Sensitization of capsaicin and icilin responses in oxaliplatin treated adult rat DRG neurons. Mol Pain 2010; 6: 82.
35. Joseph EK, Chen X, Bogen O, Levine JD . Oxaliplatin acts on IB4-positive nociceptors to induce an oxidative stress-dependent acute painful peripheral neuropathy. J Pain 2008; 9: 463-72.
36. Kim HK, Zhang YP, Gwak YS, Abdi S. Phenyl N-tert-butylnitrone, a free radical scavenger, reduces mechanical allodynia in chemotherapy-induced neuropathic pain in rats. Anesthesiology 2010; 112: 432-9.
37. Muthuraman A, Jaggi AS, Singh N, Singh D. Ameliorative effects of amiloride and pralidoxime in chronic constriction injury and vincristine induced painful neuropathy in rats. Eur J Pharmacol 2008; 587: 104-11.
38. Joseph EK, Levine JD. Caspase signalling in neuropathic and inflammatory pain in the rat. Eur J Neurosci 2004; 20: 2896-902. (Pubitemid 40007283)
39. Boehmerle W, Zhang K, Sivula M, et al. Chronic exposure to paclitaxel diminishes phosphoinositide signaling by calpain-mediated neuronal calcium sensor-1 degradation. Proc Natl Acad Sci U S A 2007; 104: 11103-8. (Pubitemid 47175233)
40. Horvath P, Szilvassy J, Nemeth J, Peitl B, Szilasi M, Szilvassy Z. Decreased sensory neuropeptide release in isolated bronchi of rats with cisplatin-induced neuropathy. Eur J Pharmacol 2005; 507: 247-52. (Pubitemid 40126861)
41. Jamieson SM, Liu JJ, Connor B, Dragunow M, McKeage MJ. Nucleolar enlargement, nuclear eccentricity and altered cell body immunostaining characteristics of large-sized sensory neurons following treatment of rats with paclitaxel. Neurotoxicology 2007; 28: 1092-8. (Pubitemid 350026583)
42. Thibault K, Van Steenwinckel J, Brisorgueil MJ, et al. Serotonin 5-HT2A receptor involvement and Fos expression at the spinal level in vincristine-induced neuropathy in the rat. Pain 2008; 140: 305-22.
43. Hansen N, Uceyler N, Palm F, et al. Serotonin transporter deficiency protects mice from mechanical allodynia and heat hyperalgesia in vincristine neuropathy. Neurosci Lett 2011; 495: 93-7.
44. Cata JP, Weng HR, Chen JH, Dougherty PM. Altered discharges of spinal wide dynamic range neurons and down-regulation of glutamate transporter expression in rats with paclitaxel-induced hyperalgesia. Neuroscience 2006; 138: 329-38. (Pubitemid 43222091)
45. Kassem LA, Gamal El-Din MM, Yassin NA. Mechanisms of vincristine-induced neurotoxicity: possible reversal by erythropoietin. Drug Discov Ther 2011; 5: 136-43.
46. Norcini M, Vivoli E, Galeotti N, Bianchi E, Bartolini A, Ghelardini C. Supraspinal role of protein kinase C in oxaliplatin-induced neuropathy in rat. Pain 2009; 146: 141-7.
47. Galeotti N, Vivoli E, Bilia AR, Vincieri FF, Ghelardini C. St. John's Wort reduces neuropathic pain through a hypericin-mediated inhibition of the protein kinase Cgamma and epsilon activity. Biochem Pharmacol 2010; 79: 1327-36.
48. Ledeboer A, Jekich BM, Sloane EM, et al. Intrathecal interleukin-10 gene therapy attenuates paclitaxel-induced mechanical allodynia and proinflammatory cytokine expression in dorsal root ganglia in rats. Brain Behav Immun 2007; 21: 686-98. (Pubitemid 46829773)
49. Kaur G, Athar M, Alam MS. Dietary supplementation of silymarin protects against chemically induced nephrotoxicity, inflammation and renal tumor promotion response. Invest New Drugs 2010; 28: 703-13.
50. Mangiacavalli S, Corso A, De Amici M, et al . Emergent T-helper 2 profile with high interleukin-6 levels correlates with the appearance of bortezomib-induced neuropathic pain. Br J J Haematol 2010; 149: 916-8.
51. Visovsky C . Chemotherapy-induced peripheral neuropathy. Cancer Invest 2003; 21: 439-51. (Pubitemid 37059093)
52. Farquhar-Smith P. Chemotherapy-induced neuropathic pain. Curr Opin Support Palliat Care 2011; 5: 1-7.
53. Windebank AJ, Grisold W. Chemotherapy-induced neuropathy. J Peripher Nerve Syst 2008; 13: 27-46. (Pubitemid 351393018)
54. Grisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro Oncol 2012; 14 Suppl 4: iv45-54.
55. Ocean AJ, Vahdat LT. Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies. Support Care Cancer 2004; 12: 619-25. (Pubitemid 39280311)
56. Lavoie Smith EM, Barton DL, Qin R, Steen PD, Aaronson NK, Loprinzi CL. Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire. Qual Life Res 2013; 22: 2787-99.
57. Urch CE, Dickenson AH. Neuropathic pain in cancer. Eur J Cancer 2008; 44: 1091-6. (Pubitemid 351672363)
58. Polomano RC, Bennett GJ. Chemotherapy-evoked painful peripheral neuropathy. Pain Med 2001; 2: 8-14. (Pubitemid 32447626)
59. Xiao WH, Bennett GJ. Chemotherapy-evoked neuropathic pain: abnormal spontaneous discharge in A-fiber and C-fiber primary afferent neurons and its suppression by acetyl-L-carnitine. Pain 2008; 135: 262-70. (Pubitemid 351330186)
60. Burton AW, Fine PG, Passik SD. Transformation of acute cancer pain to chronic cancer pain syndromes. J Support Oncol 2012; 10: 89-95.
61. Caraceni A, Brunelli C, Martini C, Zecca E, De Conno F. Cancer pain assessment in clinical trials. A review of the literature (1999-2002). J Pain Sympt Manage 2005; 29: 507-19. (Pubitemid 40724744)
62. De Conno F, Caraceni A, Gamba A, et al. Pain measurement in cancer patients: a comparison of six methods. Pain 1994; 57: 161-6. (Pubitemid 24168733)
63. Wong DL, Baker CM. Pain in children: comparison of assessment scales. Pediatr Nurs 1988; 14: 9-17.
64. Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain 1975; 1: 277-99.
65. Cleeland CS, Gonin R, Hatfield AK, et al. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 1994; 330: 592-6. (Pubitemid 24065792)
66. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994; 23: 129-38.
67. Lauria G, Hsieh ST, Johansson O, et al European Federation of Neurological Societies; Peripheral Nerve Society. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol 2010; 17(903-12): e44-9.
68. Dworkin RH, Backonja M, Rowbotham MC, et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol 2003; 60: 1524-34. (Pubitemid 37443116)
69. Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007; 132: 237-51. (Pubitemid 350051570)
70. Dworkin RH, O'Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010; 85(3 Suppl): S3-14.
71. Tsavaris N, Kopterides P, Kosmas C, et al. Gabapentin monotherapy for the treatment of chemotherapy-induced neuropathic pain: a pilot study. Pain Med 2008; 9: 1209-16.
72. Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain 2010; 150: 573-81.
73. Corbett CF. Practical management of patients with painful diabetic neuropathy. Diabetes Educ 2005; 31: 523-4.
74. Wallace M, Pappagallo M. Qutenza®: a capsaicin 8% patch for the management of postherpetic neuralgia. Expert Rev Neurother 2011; 11: 15-27.
75. Galluzzi KE . Management of neuropathic pain. J Am Osteopath Assoc 2005; 105(9 Suppl 4): S12-9. (Pubitemid 44783996)
76. Cassileth BR, Keefe FJ. Integrative and behavioral approaches to the treatment of cancer-related neuropathic pain. Oncologist 2010; 15(Suppl 2): 19-23.
77. Jung BF, Herrmann D, Griggs J, Oaklander AL, Dworkin RH. Neuropathic pain associated with non-surgical treatment of breast cancer. Pain 2005; 118: 10-4. (Pubitemid 41566580)
78. Argyriou AA, Polychronopoulos P, Koutras A, et al . Peripheral neuropathy induced by administration of cisplatin- and paclitaxel-based chemotherapy. Could it be predicted? Support Care Cancer 2005; 13: 647-51. (Pubitemid 41040187)
79. Albers JW, Chaudhry V, Cavaletti G, Donehower RC. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev 2011; (2): CD005228.
80. Argyriou AA, Chroni E, Koutras A, et al. Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial. Neurology 2005; 64: 26-31. (Pubitemid 40082932)
81. Kemp G, Rose P, Lurain J, et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 1996; 14: 2101-12. (Pubitemid 26230113)
82. Smyth JF, Bowman A, Perren T, et al. Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial. Ann Oncol 1997; 8: 569-73. (Pubitemid 127746489)
83. Gamelin L, Boisdron-Celle M, Morel A, et al. Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy. J Clin Oncol 2008; 26: 1188-9; author reply 1189-90.
84. Wang WS, Lin JK, Lin TC, et al. Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients. Oncologist 2007; 12: 312-9.
85. Kottschade LA, Sloan JA, Mazurczak MA, et al. The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial. Support Care Cancer 2011; 19: 1769-77.
86. Bianchi G, Vitali G, Caraceni A, et al. Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine. Eur J Cancer 2005; 41: 1746-50. (Pubitemid 41132636)